These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond. Ansell SM Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486 [TBL] [Abstract][Full Text] [Related]
84. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149 [TBL] [Abstract][Full Text] [Related]
85. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Al-Ali HK; Wittekind C; Niederwieser D Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864 [TBL] [Abstract][Full Text] [Related]
86. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis. Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373 [TBL] [Abstract][Full Text] [Related]
87. The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma. Burger IA; Vargas HA; Goldman DA; Gonen M; Kumar A; Zelenetz AD; Schöder H; Hricak H Eur J Nucl Med Mol Imaging; 2013 May; 40(5):701-7. PubMed ID: 23389428 [TBL] [Abstract][Full Text] [Related]
88. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751 [TBL] [Abstract][Full Text] [Related]
89. Advances in chemotherapy for large cell lymphoma. Coleman M; Gerstein G; Topilow A; Lebowicz J; Berhardt B; Chiarieri D; Silver RT; Pasmantier MW Semin Hematol; 1987 Apr; 24(2 Suppl 1):8-20. PubMed ID: 2438781 [TBL] [Abstract][Full Text] [Related]
90. Cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) for advanced-stage Hodgkin's disease: CALGB 8856. Lester EP; Petroni GR; Barcos M; Johnson JL; Millard FE; Cooper MR; Omura GA; Frei E; Peterson BA Cancer Invest; 2001; 19(5):447-58. PubMed ID: 11458812 [TBL] [Abstract][Full Text] [Related]
91. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma]. Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685 [TBL] [Abstract][Full Text] [Related]
92. The early- and intermediate-term toxicity to primitive hematopoietic progenitor cells of three chemotherapy regimens for advanced hodgkin lymphoma. Gobbi PG; Rosti V; Valentino F; Bonetti E; Merli F; Stelitano C; Dondi A; Quarta G; Falorio S; Federico M Clin Lymphoma Myeloma; 2009 Dec; 9(6):425-9. PubMed ID: 19951881 [TBL] [Abstract][Full Text] [Related]
93. Combined chemotherapy (MOPP or ABVD)-radiotherapy approach in advanced Hodgkin's disease. Bonadonna G; Zucali R; De Lena M; Valagussa P Cancer Treat Rep; 1977 Aug; 61(5):769-77. PubMed ID: 70270 [No Abstract] [Full Text] [Related]
94. Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. Carde P; Karrasch M; Fortpied C; Brice P; Khaled H; Casasnovas O; Caillot D; Gaillard I; Bologna S; Ferme C; Lugtenburg PJ; Morschhauser F; Aurer I; Coiffier B; Meyer R; Seftel M; Wolf M; Glimelius B; Sureda A; Mounier N J Clin Oncol; 2016 Jun; 34(17):2028-36. PubMed ID: 27114593 [TBL] [Abstract][Full Text] [Related]
95. [Successful treatment with brentuximab vedotin maintenance therapy after autologous stem cell transplantation in high-risk Hodgkin lymphoma]. Ishii K; Azuma Y; Konishi A; Tsubokura Y; Yoshimura H; Hotta M; Nakanishi T; Nakaya A; Fujita S; Satake A; Miyaji M; Ito T; Nomura S Rinsho Ketsueki; 2018; 59(8):1002-1006. PubMed ID: 30185698 [TBL] [Abstract][Full Text] [Related]
96. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068 [TBL] [Abstract][Full Text] [Related]
97. Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses. Gallamini A; Patti C; Viviani S; Rossi A; Fiore F; Di Raimondo F; Cantonetti M; Stelitano C; Feldman T; Gavarotti P; Sorasio R; Mulè A; Leone M; Rambaldi A; Biggi A; Barrington S; Fallanca F; Ficola U; Chauvie S; Gianni AM; Br J Haematol; 2011 Mar; 152(5):551-60. PubMed ID: 21166786 [TBL] [Abstract][Full Text] [Related]
98. Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial. Phillips T; Migliaccio-Walle K; Yu KS; Bloudek B; Liu N; Fanale M; Burke JM Leuk Lymphoma; 2023 May; 64(5):1017-1025. PubMed ID: 37074674 [TBL] [Abstract][Full Text] [Related]
99. Review of Treatment Options for the Management of Advanced Stage Hodgkin Lymphoma. Vellemans H; André MPE Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359646 [TBL] [Abstract][Full Text] [Related]
100. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution. Bartlett NL Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]